<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343120</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-AU-003</org_study_id>
    <secondary_id>2016-003364-39</secondary_id>
    <nct_id>NCT02343120</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies</brief_title>
  <official_title>A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment&#xD;
      effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2014</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From first dose to within 28 days of last dose of BGB-3111</time_frame>
    <description>Creating a safety profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast)</measure>
    <time_frame>During first 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinity time (AUC∞)</measure>
    <time_frame>During first 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>During first 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax)</measure>
    <time_frame>During first 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>During first 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BTK inhibition activity of BGB-3111 by measurement of free BTK</measure>
    <time_frame>During first 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every 12 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">397</enrollment>
  <condition>B-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>BGB-3111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undertake 160MG BID of BGB-3111.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111</intervention_name>
    <description>In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.&#xD;
In the safety, schedule and efficacy expansion part, patients will be assigned to different cohorts based on histology type.</description>
    <arm_group_label>BGB-3111</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 18 years, voluntarily consented to the study.&#xD;
&#xD;
          2. WHO classification defined B-lymphoid malignancy, with the exception of Burkitt&#xD;
             lymphoma/leukemia, plasma cell myeloma, acute lymphoblastic leukemia, lymphoblastic&#xD;
             lymphoma, and plasmablastic lymphoma.&#xD;
&#xD;
          3. Requirement for treatment in the opinion of the investigator.&#xD;
&#xD;
          4. Disease which has relapsed, or is refractory, following at least one line of therapy,&#xD;
             with no therapy of higher priority available.&#xD;
&#xD;
          5. ECOG performance status of 0-2.&#xD;
&#xD;
          6. Adequate hematologic function, as defined by neutrophils ≥ 1.0 x 10^9/L and platelets&#xD;
             ≥ 50 x 10^9/L; patients with neutrophils &lt; 1.0 x 10^9/L due to marrow infiltration are&#xD;
             allowed to receive growth factors to bring pre-treatment neutrophils to ≥ 1.0 x&#xD;
             10^9/L.&#xD;
&#xD;
          7. Adequate renal function, as defined by creatinine clearance of ≥ 50 ml/min (as&#xD;
             estimated by the Cockcroft-Gault equation or as measured by nuclear medicine scan or&#xD;
             24 hour urine collection).&#xD;
&#xD;
          8. Adequate liver function, as defined by AST and ALT ≤ 3 x ULN, and bilirubin ≤ 1.5 x&#xD;
             ULN (unless documented Gilbert's syndrome).&#xD;
&#xD;
          9. INR and APTT ≤ 1.5 x ULN.&#xD;
&#xD;
         10. Female subjects of childbearing potential and non-sterile males must practice at least&#xD;
             one of the following methods of birth control with partner(s) throughout the study and&#xD;
             for 90 days after discontinuing study drug: total abstinence from sexual intercourse,&#xD;
             double-barrier contraception, IUD or hormonal contraceptive initiated at least 3&#xD;
             months prior to first dose of study drug.&#xD;
&#xD;
         11. Male subjects must not donate sperm from initial study drug administration, until 90&#xD;
             days after drug discontinuation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current CNS involvement by disease&#xD;
&#xD;
          2. Current histologically transformed disease.&#xD;
&#xD;
          3. Prior BTK inhibitor treatment.&#xD;
&#xD;
          4. Allogeneic stem cell transplantation within 6 months, or has active GVHD requiring&#xD;
             ongoing immunosuppression.&#xD;
&#xD;
          5. Receipt of the following treatment prior to first dose of BGB-3111: corticosteroids&#xD;
             given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 2&#xD;
             weeks, monoclonal antibody within 4 weeks.&#xD;
&#xD;
          6. Not recovered from toxicity of any prior chemotherapy to grade ≤ 1.&#xD;
&#xD;
          7. History of other active malignancies within 2 years of study entry, with exception of&#xD;
             (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or&#xD;
             squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally&#xD;
             (surgery or other modality) with curative intent.&#xD;
&#xD;
          8. Uncontrolled systemic infection requiring parenteral anti-microbial therapy.&#xD;
&#xD;
          9. Major surgery in the past 4 weeks.&#xD;
&#xD;
         10. Known HIV, or active hep B or hep C infection (detected positive by PCR).&#xD;
&#xD;
         11. Cardiovascular disease resulting in New York Heart Association function status of ≥ 3.&#xD;
&#xD;
         12. Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease&#xD;
             that in the investigator's opinion would adversely impact on his/her participating in&#xD;
             the study.&#xD;
&#xD;
         13. Inability to comply with study procedures.&#xD;
&#xD;
         14. On medications which are CYP3A inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine Tam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Centre</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre, East Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Health</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola Malpighi, AOU di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Medical Centre</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>C.S. Tam M. Wang D. Simpson S. Opat G. Cull J. Munoz T.J. Phillips W. Kim S. Atwal R. Wei J. Huang R. Elstrom J. Trotman. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111). Hematological Oncology. 2019; 37(S2) DOI: https://doi.org/10.1002/hon.55_2630</citation>
  </reference>
  <results_reference>
    <citation>Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24.</citation>
    <PMID>31340982</PMID>
  </results_reference>
  <results_reference>
    <citation>Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, Munoz J, Tedeschi A, Roberts AW, Seymour JF, Atwal SK, Yu Y, Novotny W, Holmgren E, Tan Z, Hilger JD, Huang J, Tam CS. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020 Oct 29;136(18):2027-2037. doi: 10.1182/blood.2020006449. Erratum in: Blood. 2021 Feb 25;137(8):1131.</citation>
    <PMID>32698195</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

